2023年5月2日

Adcentrx疗法——一个生物科技公司致力于革新抗体药物共轭(ADC)疗法对癌症和其他危及生命的疾病——宣布关闭系列+融资3800万美元。一轮融资是由八公路企业参与,从f '资本ABio-X,δ资本,三位一体创新基金和其他战略投资者。生活Venture Partners和灯塔资本充当Adcentrx的金融顾问。Adcentrx计划通过融资所得来推进其专有的ADC治疗管道到诊所。adc的被称为一个类疗法结合的目标特异性抗体与传统化疗药物的效力。这类肿瘤的治疗发生了革命性变化景观与潜在的积极影响其他严重疾病。Adcentrx区分本身利用团队的行业领先的ADC药物开发经验以及深刻的化学和生物学方面的专长。和团队的发展开创了ADC技术工具箱解决关键组件的蛋白质结合设计解决的挑战出现在前几代的ADC。Adcentrx实现这种优化方法,燃料的开发一个健壮的管道first-in-class和最佳的治疗方法。和公司的领先候选人adrx - 0706预计进入first-in-human 1期临床试验在2023年下半年。 Plus Adcentrx is developing additional candidates in parallel with the goal of advancing at least one into the clinic each year. KEY QUOTES: “We are thrilled to have Eight Roads and our investors supporting our mission to bring innovative treatments to patients. Over the last two years, we have made significant progress advancing our emerging therapeutic pipeline that implements our proprietary and differentiated technology platform. This new round of funding from our investors will enable Adcentrx to quickly advance our safer and more efficacious conjugate therapies for patients in need. This year will be pivotal for Adcentrx, when we transition from the discovery stage into a clinical-stage company.” Hui Li, Ph.D., Founder and CEO of Adcentrx “ADCs as a therapeutic modality have flourished in recent years with a transformative inflow of active investment and strategic transactions. Adcentrx has demonstrated good potential of developing differentiated ADCs for unmet medical needs. We are very excited to lead this round of financing to empower Adcentrx to accelerate its work in bringing new hope to patients in need.” Tao Huang, Ph.D., Principal of Eight Roads Ventures “Through its innovative work in the ADC field, Adcentrx exemplifies the type of company that ABio-X was designed to support as a global platform for developing the next generation healthcare companies. We are pleased to join together with other quality investors in this financing round and look forward to continuing our support of Adcentrx through the platform and board representation.” Jeff Jonas, President and CEO of ABio-X “Adcentrx has made significant progress in building its preclinical pipeline and platform technology since our initial investment. Together with our ABio-X colleagues, we are pleased to reaffirm our commitment to support the company’s continued growth and development.” Meng Jiang, Head, Venture Capital at CBC Group “As an innovation company with a global vision, Adcentrx leverages its technology platform to address the challenges of ADC drug development. It is a privilege to participate in this round of financing that attracted investment from renowned funds and industry players, indicating the company’s growing prominence within the industry. We look forward to Adcentrx’s continued progress of advancing its novel ADCs into the clinic.” Lei Hong, Executive Director of Lighthouse Capital Trending on Pulse 2.0